NLS Pharmaceutics AG (NLSP) stock has hit a 52-week low, trading at $1.73, with a market capitalization of just $2.94 million ...

Dylan Berman What's Going On With NLS Pharmaceutics Shares Monday? NLS Pharmaceutics shares are moving higher on Monday after the company announced it entered into a definitive merger agreement ...

This course is designed to give students an understanding of the basic physical chemistry needed to determine drug dosing and knowledge of how drugs are delivered through the body. Upon completion of ...

NLS Pharmaceutics and Kadimastem have filed a Registration Statement with the SEC in preparation for a proposed merger, creating a Nasdaq-traded biotechnology entity. This merger aims to leverage ...

NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central ...

RSC Pharmaceutics acknowledges how chemistry and related disciplines can make a big difference. This impactful journal provides you with a platform to publish crucial research on pharmaceutics. This ...

The Registration Statement contains a prospectus in connection with the proposed merger transaction pursuant to the definitive agreement entered between the companies, as well as a proxy statement ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks NLS Pharmaceutics ( (NLSP)) has shared an update. NLS Pharmaceutics and Kadimastem, in collaboration with ...

NLS Pharmaceutics (NLSP) and Kadimastem announced that Kadimastem has issued a notice to convene a special general meeting of Kadimastem’s ...

Keep learning. Excel in your career. Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.

She gained her undergraduate degree in Applied Chemistry and subsequent PhD in Pharmaceutics, from Robert Gordon University, Aberdeen. Following this she carried out a postdoc at the University of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...